Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BCEL |
---|---|---|
09:32 ET | 7868 | 0.08 |
09:56 ET | 1500 | 0.083915 |
10:06 ET | 500 | 0.0801 |
10:10 ET | 200 | 0.0825 |
10:51 ET | 126 | 0.0801 |
10:55 ET | 525 | 0.0801 |
11:04 ET | 8989 | 0.085 |
11:26 ET | 830 | 0.0801 |
11:44 ET | 57793 | 0.08228 |
11:45 ET | 3350 | 0.08 |
11:47 ET | 5000 | 0.08636 |
11:49 ET | 5000 | 0.08636 |
12:16 ET | 3000 | 0.08535 |
12:18 ET | 6000 | 0.08535 |
12:38 ET | 2000 | 0.0802 |
12:45 ET | 1100 | 0.0864 |
01:21 ET | 200 | 0.08535 |
01:26 ET | 1400 | 0.0801 |
01:33 ET | 4000 | 0.08535 |
01:37 ET | 200 | 0.0801 |
01:48 ET | 24204 | 0.08 |
01:51 ET | 5000 | 0.08636 |
01:53 ET | 10000 | 0.0801 |
01:55 ET | 1200 | 0.08636 |
01:57 ET | 7000 | 0.0906 |
02:02 ET | 200 | 0.0801 |
02:26 ET | 1212 | 0.0801 |
03:09 ET | 250 | 0.0825 |
03:18 ET | 1200 | 0.0802 |
03:36 ET | 100 | 0.08 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Atreca Inc | 3.2M | 0.0x | --- |
Transcode Therapeutics Inc | 3.2M | 0.0x | --- |
Phio Pharmaceuticals Corp | 3.1M | -0.1x | --- |
Mustang Bio Inc | 3.3M | -0.1x | --- |
GeoVax Labs Inc | 3.3M | -0.1x | --- |
Evolutionary Genomics Inc | 3.0M | -1.3x | --- |
Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. It is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.2M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 39.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.06 |
EPS | $-2.49 |
Book Value | $2.01 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.